knowledge -WSS

knowledge

author：entertainment 2025-09-06 10:44:53 - browse：4

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Readout LOUD podcast: Live from STAT Breakthrough Summit West

WSS

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

When prostate cancer spreads, where it goes matters

Chimpanzees, like humans and whales, get menopause: Study

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Testing for cancer recurrence creates a new limbo for patients

knowledge

knowledge

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Wearables generate powerful data but its not useful to doctors, yet

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Peter Hotez and the public health issue of online harassment

Case highlights the risks of experimental stem cell therapy

BioMarin wins approval for gene therapy to treat hemophilia A

Solving academic medical centers' existential crisis

Hollywood unions extend contract negotiations for actors

Case highlights the risks of experimental stem cell therapy

Wikipedia

Maker of FluMist seeks to allow at

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Emergency medicine has repudiated 'excited delirium.' Now what?

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

The pink breast cancer awareness ribbon needs a redesign

leisure time

leisure time

explore

hotspot